ReviewFrontiers in medical technology2022
Orchestrating the fecal microbiota transplantation: Current technological advancements and potential biomedical application.
Review in Frontiers in medical technology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Engineering the Gut Microbiome: Emerging Genome-Editing Strategies and Therapeutic Applications.Microorganisms · 2026Review
- Fecal microbiota transplant and its usefulness in hepatic disorders: a systematic review.Therapeutic advances in gastroenterology · 2026Review
- Role of Gut Microbiome in Oncogenesis and Oncotherapies.Cancers · 2025Review
- Gut microbiota profile, potential engineering techniques and its genetic and epigenetic implications in poultry health.World journal of microbiology & biotechnology · 2025Review
- The pulmonary commensal Lactobacillus regulated lung γδ T cells to enhance resistance against bacterial infections.Microbiome · 2025Article
- The Gut Microbiome in Enteric Viral Infections: Underlying Mechanisms and Therapeutic Approaches.Microorganisms · 2025Review
- Advancements in Immunomodulatory Therapies for IBD and Their Interplay With the Gut-Brain Axis: An Updated Review of Current Literature and Beyond.Health science reports · 2025Article
- Microbial Crosstalk with Therapy: Pharmacomicrobiomics in AML-One Step Closer to Personalized Medicine.Biomedicines · 2025Review
- Could a Mediterranean Diet Modulate Alzheimer's Disease Progression? The Role of Gut Microbiota and Metabolite Signatures in Neurodegeneration.Foods (Basel, Switzerland) · 2025Review
- Modulation of the Neuro-Cancer Connection by Metabolites of Gut Microbiota.Biomolecules · 2025Review
- Unraveling the Gut-Liver-Brain Axis: Microbiome, Inflammation, and Emerging Therapeutic Approaches.Mediators of inflammation · 2025Review
- Detection of Human Y Chromosome and theGastro hep advances · 2025Article
- The Relationship between Canine Behavioral Disorders and Gut Microbiome and Future Therapeutic Perspectives.Animals : an open access journal from MDPI · 2024Review
- Effects of the gut microbiota and its metabolite short-chain fatty acids on endometriosis.Frontiers in cellular and infection microbiology · 2024Review
- Unveiling the dynamics of gut microbial interactions: a review of dietary impact and precision nutrition in gastrointestinal health.Frontiers in nutrition · 2024Review
- Using the Microbiome as a Regenerative Medicine Strategy for Autoimmune Diseases.Biomedicines · 2023Review
- Targeting Gut Microbiota in Cancer Cachexia: Towards New Treatment Options.International journal of molecular sciences · 2023Review
- Role of probiotics in managing various human diseases, from oral pathology to cancer and gastrointestinal diseases.Frontiers in microbiology · 2023Review
- The gut microbiota and endometriosis: From pathogenesis to diagnosis and treatment.Frontiers in cellular and infection microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fecal microbiota transplantation (FMT) has been proved to be an effective treatment for gastrointestinal disorders caused due to microbial disbalance. Nowadays, this approach is being used to treat extragastrointestinal conditions like metabolic and neurological disorders, which are considered to have their provenance in microbial dysbiosis in the intestine. Even though case studies and clinical trials have demonstrated the potential of FMT in treating a variety of ailments, safety and ethical concerns must be answered before the technique is widely used to the community's overall benefit. From this perspective, it is not unexpected that techniques for altering gut microbiota may represent a form of medication whose potential has not yet been thoroughly addressed. This review intends to gather data on recent developments in FMT and its safety, constraints, and ethical considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.